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Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of cer-
tain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other 
medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, 
bevacizumab or aflibercept. Very recently, new medications have also been associated with osteonecrosis of the 
jaw (ONJ). The objectives were to update the list of medications associated with ONJ, to analyze the fundamental 
aspects of this list and to describe the level of evidence available.
Material and Methods: A narrative bibliographic review was made, using the PubMed-MedLine, DOAJ and SCI-
ELO databases. Additional information was obtained through the online Medication Information Centre of the 
Spanish Agency of Medicines and Medical Devices (AEMPS – CIMA), the websites of the US Food & Drugs 
Administration (Drugs@FDA) and the European Medicines Agency (EMA).
Results: The latest drugs identified as potential facilitators of this pathology include a number of anti-VEGF based 
antiangiogenic drugs and anti-TKI and different types of immunomodulators. Neither the level of evidence in this 
association nor the risk are equal for all these drugs. On the other hand, over the coming years, new drugs will be 
marketed with similar action mechanisms to those that are recognized as having this adverse effect.
Conclusions: No effective therapy is currently known for the treatment of ONJ. Therefore, in order to prevent new 
cases of MRONJ, it is essential for all oral healthcare professionals to be fully up-to-date with the etiopathogenic 
aspects of this pathology and to be aware of those drugs considered to be a risk.
Key words: Osteonecrosis of the jaw, MRONJ, bisphosphonates, antiresorptives, antiangiogenics.
doi:10.4317/medoral.23191
http://dx.doi.org/doi:10.4317/medoral.23191
Eguia A, Bagan L, Cardona F. Review and update on drugs related to the 
development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 
2020 Jan 1;25 (1):e71-83.
http://www.medicinaoral.com/pubmed/medoralv25_i1_p71.pdf
Article Number:23191          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
e72
Med Oral Patol Oral Cir Bucal. 2020 Jan 1;25 (1):e71-83. MRONJ: Review and update
Introduction
Osteonecrosis of the jaw (ONJ) is a rare, but serious pa-
thology and can affect both jaws, although it is more 
common in the mandible. It manifests itself as one or 
Ruggiero et al. 
2006 (5)
Stage 1:
Exposure of necrotic bone which is asymptomatic.
Stage 2:
Exposed necrotic bone associated with pain and infection
Stage 3:
Exposed necrotic bone in patients with pain, infection and pathological fracture, extraoral fistula or osteolysis 
which extends to the inferior border.
McMahon et al. 
2007 (6)
Stage 1:
Non-exposed / necrotic bone.
Moderate and intermittent jaw pain.
Dental findings /normal mucosas and X-rays
Gammagraphy, CT and MR reveal osteoblast activity but there is no evident infection.
Stage 2:
Non-exposed / necrotic bone.
Moderate and constant jaw pain.
Dental findings / normal mucosas but the X-rays reveals sclerotic changes
and radiotransparencies
The gammagraphy, CT and MR show alterations.
There is no evidence of infection.
Stage 3:
There is no apparent exposed / necrotic bone.
Severe, constant jaw pain requiring analgesic drugs.
Mucosal edema, erythema with severe pain of the alveolar bone.
Dental X-ray, gammagraphy, CT and MR show alterations.
There may be infection, although not of dental origin.
Stage 4:
<2 cm of exposed / necrotic bone without cortical fenestration.
Considerable, constant jaw pain requiring potent analgesic drugs.
The mucosa surrounding the exposed bone is red and swollen.
Swelling of the surrounding tissues, with no clear evidence of infection.
Dental XR, CT and MR show alterations.
Dental pathology ruled out.
Stage 5:
> 2 cm of exposed / necrotic bone with or without cortical fenestration.
Severe, constant jaw pain requiring analgesic drugs.
The mucosa surrounding the exposed bone is red and swollen.
Slight to moderate swelling of the peripheral tissues with or without
purulent suppuration.
Dental XR, gammagraphy, CT and MR show alterations.
Dental pathology ruled out.
Stage 6:
> 4 cm of exposed / necrotic bone with cortical fenestration and infection.
Severe and constant jaw pain.
Fetid smell, the mucosa surrounding the exposed bone is red and swollen.
At least one of the following: pathologic fracture, extraoral fistula, oroantral fistula or osteolysis extending to the 
inferior mandibular margin.
Dental XR, bone gammagraphy with radioisotopes, CT and MR show alterations.
Dental pathology ruled out.
more necrotic bone lesions, generally exposed in the 
oral cavity and which persist for at least 8 weeks (1-4). 
Numerous proposals (5-17) have been put forward with 
regard to the staging of ONJ as can be seen in Table 1.
Table 1: Osteonecrosis of the Jaw Staging Proposal by drugs. 
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Ruggiero et al. 
2009 (7)
Classification of the AAOMS (American Association of Oral and Maxillofacial Surgeons)
Risk category:
There is no apparent necrotic bone in patients who have been treated with intravenous or oral bisphosphonates.
Stage 0:
There is no clinical evidence of necrotic bone, clinical findings or non-specific symptoms.
Stage 1:
Exposed necrotic bone in asymptomatic patients who present no evidence of infection.
Stage 2:
Exposed necrotic bone associated with infection, with pain and erythema in the exposed bone area with or with-
out purulent drainage.
Stage 3:
Exposed necrotic bone in patients with pain, infection and one or more of the following: exposed necrotic bone 
extending beyond the region of alveolar bone (that is, the lower border and ramus of mandible, the maxillary sinus 
and maxillary zygoma) 
Pathologic fracture, extraoral fistula, oral antral / oral nasal communication or osteolysis extending to the lower 
border of the mandible of sinus floor.
Mawardi et al. 
2009 (8)
Proposal for the modification of the 2009 AAOMS classification, introducing a new stage called 0s.
Stage 0s: “suspected ONJ”
No exposed bone. 
Presence of fistulas, severe tooth movement, deep periodontal pockets, positive radiographic findings.
2 subcategories:
Stage 0ss: “suspect” and symptomatic.
Stage 0sa: “suspect” and asymptomatic.
Bagán et al. 
2009 (9)
Stage 1:
Presence of exposed necrotic bone or small oral fistula with no exposure of the necrotic bone. Asymptomatic.
Stage 2a:
Presence of exposed necrotic bone or small oral fistula with no exposure of the necrotic bone.
Patient with symptoms controlled by medical treatment.
Stage 2b:
Presence of exposed necrotic bone or small oral fistula with no exposure of the necrotic bone.
Patient with symptoms not controlled by medical treatment.
Stage 3:
Pathologic fracture, extraoral fistula, osteolysis extending to the inferior mandibular margin.
Yoneda et al. 
2010 (10)
The same specifications as the AAOMS in its 2009 classification, except:
Stage 0
Includes  hypoesthesia or anesthesia of the lower lip and/or deep periodontal pockets 
Bagán et al. 
2012 (11)
The same stages as the classification of the AAOMS in 2009, but also:
Stage 3: 
Exposed necrotic bone or oral fistula with no exposed bone, in patients with pain, infection and one or more of 
the following: radiographic evidence of bone necrosis extending beyond the alveolar bone, pathological fracture, 
extraoral fistula, oronasal communication, osteolysis extending to the inferior mandibular margin or sinus floor.
Bedogni et al. 
2012 (12)
Stage 1 - Focal ONJ
Clinical signs and symptoms: bone exposure, tooth mobility, no post-extraction healing, fistula, inflammation, 
abscess formation, trismus, important mandibular deformity and / or lip hypoesthesia. 
CT findings: increased bone density limited to alveolar bone
(trabecular thickening and / or focal osteosclerosis), with or without the following signs: sclerotic and markedly
thickened lamina dura, persistent socket space and / or cortical disruption.
1a. Asymptomatic
1b. Symptomatic (pain and purulent secretion)
Stage 2 - Diffuse ONJ
Clinical signs and symptoms: the same as for stage 1.
CT findings: increased bone density extending to the basal layer (diffuse osteosclerosis), with or without the fol-
lowing signs: inferior dental nerve canal prominence, periosteal reaction, sinusitis, bone sequestration and / oro-
antral communication.
2a. Asymptomatic
2b. Symptomatic (pain and purulent secretion)
Stage 3 - Complicated ONJ
As for stage 2, with one or more of the following:
Clinical signs and symptoms: extraoral fistula.
Mandibular stump displacement, nasal fluid drainage.
CT findings: osteosclerosis of adjacent bone (zygoma, hard palate), pathological mandibular fracture and / or 
osteolysis extending to the sinus floor.
Table 1 cont.: Osteonecrosis of the Jaw Staging Proposal by drugs. 
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Patel et al.
2012 (13)
Modification of AAOMS 2009 classification
No exposed bone (NE)
Asymptomatic
Stage 1NE
No clinical evidence of infection; radiographic findings may be present.
Symptomatic
Stage 2NE
Non-exposed necrotic bone; clinical evidence of infection, presence of intraoral sinus tracts, swelling, pain, pares-
thesia/dysesthesia and radiographic evidence of bone necrosis.
Stage 3NE
Non-exposed necrotic bone; pain, clinical evidence of infection and symptoms as stage 2 NE, and one or more of:
• Radiographic evidence of necrotic bone extending beyond alveolar bone
• Pathologic fracture
• Extraoral fistula
• Oral antral/oral nasal communication
• Osteolysis extending to the inferior border of the mandible or sinus floor
Schiodt et al. 
2014 (14)
Modification of classification of AAOMS of 2009 and Patel et. al. (2012)
Criteria for bone exposure (E-ONJ)
- Bone exposure
Asymptomatic
Name: E-ONJ, Stage 1
- Bone exposure
Clinical symptoms of infection
Name: E-ONJ, Stage 2
The same criteria as stage 3 of AAOMS 
Name: E-ONJ, Stage 3
Criteria for no bone exposure (E-ONJ)
- No bone exposure
Asymptomatic
Name: NE-ONJ, Stage 1
- No bone exposure
Clinical symptoms of infection
Name: NE-ONJ, Stage 2
No bone exposure, with necrosis in patients with pain, infection, and one or more of the following:
- Necrotic bone without exposure, as evidenced by imaging techniques, extending beyond the alveolar bone, that 
is, inferior border and ramus of the mandible, maxillary, sinus, and zygoma in the superior maxillary.
- Pathologic fracture
- Extraoral fistula
- Oral antral/oral nasal communication
- Osteolysis extending to the inferior border of the mandible or sinus floor
Name: NE-ONJ, Stage 3
Franco et al. 
2014 (15)
Clinical and radiological findings.
Stage 0:
No exposed bone, with non-specific radiographic findings, such as osteosclerosis and non-specific symptoms such 
as pain.
Stage I:
Exposed bones and / or radiographic evidence of necrotic bone or persistent socket space >2 cm with or without 
pain.
Stage II:
Exposed bones and / or radiographic evidence of necrotic bone, between 2-4 cm in diameter, with pain that re-
sponds to NSAIDs and possible abscesses.
Stage III:
Exposed bones and / or radiographic evidence of necrotic bone, >4 cm in greater diameter, with intense pain that 
responds or does not respond to NSAIDs, abscesses, maxillary sinus fistulization, or mandibular nerve involve-
ment.
Table 1 cont.: Osteonecrosis of the Jaw Staging Proposal by drugs. 
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Mawardi et al. 
2015 (16)
Stage 1:
Asymptomatic, with bone exposure (stage 1E) or with no bone exposure (stage 1NE).
Stage 2:
Pain and infection with bone exposure (stage 2E) or with no bone exposure (stage 2NE).
Stage 3:
Greater impact, with pain and infection with bone exposure (stage 2E) or with no bone exposure (stage 2NE).
Yoneda et al.
2017 (17)
Proposal by the Japanese Committee on Osteonecrosis of the jaw
Stage 0 *
Clinical symptoms: no bone exposure or bone necrosis, deep periodontal pocket, loose tooth, oral mucosal ulcer, 
swelling, abscess formation, trismus, hypoesthesia / numbness of the lower lip (Vincent’s symptom), non-odonto-
genic pain.
Image findings: sclerotic alveolar bone, thickening and sclerosis of the lamina dura, remaining tooth extraction 
socket.
*(Care should be taken to avoid over-diagnosis given that half the stage 0 ARONJ cases do not progress to ONJ)
Stage 1
Clinical symptoms: asymptomatic bone exposure / necrosis with no sign of infection, or fistula in which the bone 
is palpable with a probe.
Image findings: sclerotic alveolar bone, thickening and sclerosis of the lamina dura, remaining tooth extraction 
socket.
Stage 2
Clinical symptoms: bone exposure / necrosis associated with pain, infection, fistula in which the bone is palpable 
with a probe, or at least one of the following symptoms, including bone exposure / necrosis over the alveolar bone 
(for example, reaching the mandibular inferior border or mandibular ramus, or reaching the maxillary sinus or 
mandibular ramus), resulting in a pathologic fracture, extraoral fistula, nasal / maxillary sinus fistula formation, 
or advanced osteolysis extending to the mandibular inferior border or maxillary sinus. 
Stage 3
Clinical symptoms: bone exposure / necrosis associated with pain, infection or at least one of the following 
symptoms, or a fistula in which bone is palpable with a probe. Bone exposure / necrosis over the alveolar bone 
(for example, reaching the mandibular inferior border or mandibular ramus, or reaching the maxillary sinus or 
mandibular ramus or the cheekbone). As a result, pathologic fracture, or extraoral fistula, nasal / maxillary sinus 
fistula formation, or advanced osteolysis extending to the mandibular inferior border or maxillary sinus
Image findings: osteosclerosis / osteolysis of the surrounding bone, pathologic mandibular fracture and osteolysis 
extending to the maxillary sinus floor.
MR: Magnetic resonance, CT: Computed tomography, XR: X-ray, ONJ: Osteonecrosis of the Jaw, NSAIDs: non-steroidal anti-inflammatory 
drugs; ARONJ: Antiresorptive Agent-related Osteonecrosis of the Jaw.
Table 1 cont.: Osteonecrosis of the Jaw Staging Proposal by drugs. 
It may be accompanied by pain, inflammation, loose 
teeth, erythema and suppuration. Although ONJ may 
occur spontaneously, in most cases it is a result of bone 
surgery: a tooth extraction or implant surgery, in pa-
tients who, prior to or immediately afterwards, have 
received pharmacological treatment with bisphospho-
nates, antiresorptive biologic agents or other medica-
tions detailed herein (1-4,18). Fig. 1.
ONJ has a long history, dating back to the end of the 
19th century, when it was first described using the term 
“phossy jaw” for workers (primarily women) in match 
making factories. These factories used white or yellow 
phosphorous in the manufacture of matches, prior to the 
Berne convention in 1906, which limited its use. This 
raw material was highly toxic and contained pyrophos-
phate that was inhaled by the workers, leading to the ap-
pearance of ONJ as well as other serious diseases (19,20). 
In 2003, R.E. Marx (1) published an article in which, for 
the first time, the appearance of 36 cases of ONJ was 
associated with the use of intravenous bisphosphonates 
(zoledronate and pamidronate) in patients with multiple 
myeloma or metastatic breast cancer. From then on-
wards, numerous cases of ONJ associated with the use 
of systemically and orally administered bisphospho-
nates have been published (1-4,18). Today, this relation-
ship between bisphosphonates and ONJ is well-known, 
and a number of entities and associations have drafted 
guidelines and protocols for the prevention and treat-
ment of this pathology (21-23).
Initially, the term BRONJ (Bisphosphonate Related Os-
teoNecrosis of the Jaws) was established to name this po-
tential adverse effect (24). However, with the discovery 
that other medications such as the anti-RANK biologic 
antiresorptive agent (denosumab) (25) or the anti-VEGF 
antiangiogenic agent (bevacizumab) (26) and the TKI in-
hibitor (sunitinib) (27) could also be related to ONJ, from 
2014 onwards, the term BRONJ was progressively replaced 
with MRONJ (Medication Related OsteoNecrosis of the 
Jaws) on the recommendation of the American Associa-
tion of Oral and Maxillofacial Surgeons (AAOMS) (21).
e76
Med Oral Patol Oral Cir Bucal. 2020 Jan 1;25 (1):e71-83. MRONJ: Review and update
At present, there is a growing list of drugs that could 
potentially cause ONJ, with varying levels of evidence. 
Although the risk of this serious adverse effect occur-
ring varies considerably from one medication to anoth-
er, it is also dependent on factors such as administration 
guidelines and dosage, length of treatment and the exis-
tence of concomitant systemic pathologies (4,18,21,22). 
In view of the imminent marketing of a number of bio-
similar drugs and new biologic drugs, it is logical to 
foresee the continued growth of the list of ONJ-related 
drugs over the coming years.
Currently, there is no effective treatment for MRONJ 
(28) and therefore prevention is essential. This paper 
aims to review fundamental aspects of this pathology, 
to update the list of drugs that are potentially related 
to this adverse effect, and also to review the available 
evidence and the level of risk of the latest medications 
identified in the literature. The purpose is to ensure that 
all healthcare professionals are aware of the possibil-
ity of the occurrence of this pathology and to remind 
them which medications require the application of the 
MRONJ prevention guidelines and protocols.
Material and Methods
A bibliographic review was made, using the PubMed-
MedLine, DOAJ and SCIELO databases and different 
combinations of the terms included in the Medical Sub-
ject Headings (MeSH) of the Index Medicus/Medline: 
“osteonecrosis”, “jaw”, “Bisphosphonate-Associated 
Osteonecrosis of the Jaw”, “antiresorptive drugs”, 
“angiogenesis inhibitors” and “immunosuppressive 
agents”. Additionally, to complete the search, the fol-
lowing terms were employed: “antiangiogenic”, “drug-
related”, “drug-induced”, “MRONJ”, “ARONJ”, “ONJ”, 
“BRONJ” and “antiresorptive”. Additional information 
sources were also used: the CIMA application (online 
Medication Information Centre) of the Spanish Agency 
of Medicines and Medical Devices (AEMPS), the web-
sites of the US Food & Drugs Administration (Drugs@
FDA) and the European Medicines Agency (EMA).
Results
The medications related to MRONJ cases in the 
scientific literature were classified by pharmacological 
groups, as indicated below:
- Bisphosphonates
Bisphosphonates are used in the treatment of some 
skeletal dysplasias such as osteogenesis imperfecta 
or Paget’s disease, osteoporosis and the prevention of 
hypercalcemia and bone events associated with bone 
metastases (1-4,18). Intravenously, they are primarily 
used in patients suffering from solid tumor bone metas-
tases such as breast, prostate, bladder, lung and kidney 
and some lymphoproliferative processes (1-4,18). By 
contrast, bisphosphonates are primarily orally admin-
istered to patients suffering from osteoporosis. These 
drugs are able to bind to the bone matrix and, once re-
leased during bone resorption, they are able to induce 
Fig. 1: 92-year-old woman. Treated with risedronate for five years due to spinal compression. History of 
tooth removal on the left side of mandible 4 months earlier. Exposed bone at the lingual side of lower left 
premolars, suppuration at this level (B) and a cutaneous fistula (A). C: The OPG shows extensive affected 
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Table 2: Bisphosphonates marketed in 2019. AEMPS – CIMA: Spanish Agency of Medicines and Medical Devices, Drugs@FDA: Archives of 
the US Food & Drugs Administration, EMA: European Medicines Agency.
the apoptosis of the osteoclasts (29). Due to this binding 
capacity, their effects can last for up to 10 years after 
treatment discontinuation (21). Although its mechanism 
of action is known, its relationship with the ONJ etio-
pathogenesis is only partially known (4,18).
The risk of ONJ in patients taking bisphosphonates de-
pends on a number of factors, being significantly greater 
in: patients receiving intravenous administration, those 
accumulating a higher dose and for a longer period of 
time, those being administered corticoids concomitant-
ly or suffering from other systemic pathologies such as 
diabetes or inflammatory joint pathology (4,18,21). To-
bacco is probably also a negative influence, given its 
capacity to produce changes in the oral epithelium, to 
delay wound healing and to worsen the periodontal pa-
thology (30). The relative potency of bisphosphonate is 
another factor that has been related to the risk of ONJ 
(31). “Non-nitrogenated” bisphosphonates such as eti-
dronate and clodronate have the lowest potency and, 
therefore, offer a lower risk. They are principally used 
in rare bone dysplasias and dystrophies such as Paget’s 
disease (31). Risedronate, ibandronate and alendronate 
are orally administered and are primarily used in pa-
tients with osteoporosis. Their relative potency is 10 to 
100 times higher than the ones mentioned above and 
the prevalence of ONJ among patients is estimated at 
between 0.1% (10 cases/10,000) and 0.21% (21 cas-
es/10,000), with the risk significantly increasing from 
the fourth year of treatment onwards (21,32). Pamidro-
nate and zoledronate have a potency that is between 100 
to 1000 times higher than the non-nitrogenated bisphos-
phonates and are administered intravenously, primarily 
in cancer patients. These are the ones at greatest risk 
and incidence data have been published with a variation 
between 0.7% and 6.7% of patients (21,33,34). In small-
er prospective studies, as far as the number of patients 
is concerned, prevalence figures of over 23% have been 
published (35).
The risk of ONJ in cancer patients not treated with 
antiresorptives, such as those assigned to the placebo 
group in controlled clinical trials, varies between 0% 
and 0.019%. Analyzing this and other available data, it 
can be seen that the risk of ONJ in cancer patients treat-
ed with zoledronate is between 50 to 400 times greater 
than for those not receiving antiresorptives (36,37).
Table 2 shows the list of bisphosphonates currently on 
the market, together with their brand name and route of 
administration. 













PO Bonefos® Clasteon®, Clodron®, Clody®, Difosfonal®, Lodronat®, 
Loron®, Lytos®, Moticlod®, Neogrand®, Niklod®, Os-
tac®, Osteonorm®, Sindronat®, Traxovical®
Alendronate
(Alendronic Ac.) 






*Other brand names in Europe (>100): 










*Other brand names in Europe (>50):
List of nationally authorised medicinal products. Ac-
tive substance: alendronate




PO Skelid® (Withdrawn 2014) Tiludronate disodium (Withdrawn)
Pamidronate
(Pamidronic Ac.)
IV Generic: Pamidronate Pamidronate disodium
Aredia®
*Other brand names in Europe (>50):
List of nationally authorised medicinal products. Ac-
tive substance: alendronate








Boniva®, Bondenza®, Bondronat®, Bonviva®, Iasibon®
Zoledronate
Zoledronic Ac.
IV Generic: Zoledronic Ac. Zoledronic Acid
Zometa®, Reclast®
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-  Biologic antiresorptives
Currently, denosumab (Prolia®, Xgeva®) is the 
main biologic antiresorptive associated with MRONJ 
(18,19,21,35). Denosumab is a humanized monoclonal 
IgG2 antibody that selectively binds to the ligand of the 
Receptor Activator of Nuclear Factor κβ (anti-RANKL) 
interfering in the system that regulates the bone metab-
olism, RANKL/RANK/OPG, emulating the biological 
effect of osteoprotegerin (OPG) (38).  This selective 
blocking of the RANK ligand inhibits the activity and 
reduces the survival of the osteoclasts, resulting in a 
reduction in bone resorption and increased bone den-
sity (38).  Unlike bisphosphonates, denosumab does not 
permanently bind to the bone matrix and, therefore, the 
residual effect on the remodeled bone could be minimal 
after 12-24 months after treatment cessation (21,38,39). 
However, the number of studies on the residual effects 
of denosumab following discontinuation are limited and 
with only a small number of patients (39,40).
Denosumab is suitable for the treatment of osteoporo-
sis and the prevention of skeletal-related events (patho-
logic fracture, spinal cord compression, hypercalcemia) 
in adults with solid tumor bone metastases (28-40). In 
2010, shortly after it was clinically introduced, the first 
cases of osteonecrosis related to its use, started to be 
published (25). Initially, the first cases were described 
for patients that had previously been administered 
bisphosphonates, however, subsequently, numerous 
cases have been described of patients that have not been 
treated with bisphosphonates and patients that were not 
given denosumab for an oncology process (38-40). The 
pathogenic mechanism that could facilitate the appear-
ance of ONJ is only partially known and presents some 
differences of interest compared to bisphosphonates, 
both with regard to its antiangiogenic side effects and 
its immunomodulatory effects (41). In clinical terms, 
the lesions show no difference to those associated with 
bisphosphonates, however in some cases they could 
have a better response to treatment (40). Fig. 2.
 Today, the risk of ONJ in cancer patients under treat-
ment with denosumab is estimated to be comparable to 
the risk of patients treated with zoledronate, and is es-
timated to be between 0.7% and 1.9% (21,28-41). With 
regard to patients treated for osteoporosis, the risk could 
be far lower, estimating it to be around 0.04% (42).
- Antiangiogenics: Anti-VEGF and Anti-TKIs
Antiangiogenics are substances of a different nature, 
capable of inhibiting the formation of new vessels. Due 
to this capacity, they are principally employed in on-
cology, given that neoangiogenesis is an essential pro-
cess for the growth of tumors and the development of 
metastasis in some solid tumors (43). Of the numerous 
group of antiangiogenic drugs, the anti-VEGF (Vascu-
lar Endothelial Growth Factor Inhibitors) and the anti-
TKI (Tyrosine Kinase Inhibitors) appear to be related 
to a greater risk of causing MRONJ (18,19,23). The 
precise etiopathogenesis of the ONJ associated with 
antiangiogenic drugs is not well know although, logi-
cally, the inhibition of angiogenesis negatively affects 
the bone regeneration capacity following bone aggres-
sion, delaying remodeling, healing and even increasing 
susceptibility to superinfection (44,45). Furthermore, 
these drugs have other effects. For example, bevaci-
zumab and other anti-VEGF can inhibit macrophage 
chemotaxis and osteoblast differentiation (46) and suni-
tinib and other anti-TKIs can inhibit osteoclast differ-
entiation and other cells of the monocyte / macrophage 
system, conditioning the local response of the immune 
system (47).
In 2008, the first cases of ONJ were published for can-
cer patients under treatment with bevacizumab (26), 
in 2009 with sunitinib (27) and subsequently in 2016 
with aflibercept (48). Initially, some of the first clini-
cal cases had previous or simultaneously received 
bisphosphonates and other risk medications. However, 
shortly afterwards, dozens of new cases started to be 
published for patients solely treated with these medica-
tions (4,18,44).  
Fig 2: 50-year-old male, HIV+, in treatment for depression and osteoporosis with denosumab (Prolia) for two years. He presented 
to the clinic because four months ago a lower molar was extracted and it does not heal. The patient was asymptomatic. B: Detail of 
the OPG showing poor ossification.
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The last 5 years have also seen the publication of new 
cases of MRONJ associated with other antiangiogen-
ics such as Dasatinib (49,50), Erlotinib (50), Imatinib 
(50,51), Axitinib (52), sorafenib (53) and cabozantinib 
(54). Therefore, these could be considered to be risk 
medications for MRONJ. However, for many of these 
medications, it has not been possible to quantify the said 
risk with a certain level of evidence, neither is the etio-
pathogenic relationship fully known. Moreover, there is 
no solid evidence to determine the exact duration of the 
said risk following treatment discontinuation.
The ONJ cases associated with antiangiogenic drugs 
may appear spontaneously or following surgery and, 
as is the case with antiresorptives, they are also more 
common in the mandible. The time between the start of 
treatment and the appearance of ONJ is extremely vari-
able, ranging from a few weeks to 15 months (45,49-55). 
Table 3 gives a list of the antiangiogenic drugs that have 
been related to cases of MRONJ, together with their 
brand name and route of administration.
- Biologic immunomodulators
Biologic immunomodulators are medications, generally 
humanized monoclonal antibodies, specifically 
designed to selectively bind to one of the inflammatory 
response mediators (56,57). Their inclusion in the 
battery of therapeutic products available has led to a 
tremendous advance in quality of life and a reduction 
in the severe side effects of other treatment alternatives 
for patients suffering from Crohn’s disease, rheumatoid 
arthritis, ulcerative colitis, ankylosing spondylitis, 
or psoriatic arthritis among other diseases (56,57). 
As well as being indicated for this use, they are also 
useful in the treatment of some cancer processes. Very 
recently, isolated cases of ONJ have been described in 
the scientific literature, associated with the treatment 
of some of these medications such as infliximab 
(anti-TNFα) (58), adalimumab (anti-TNFα) (59,60) or 
rituximab (anti-CD20) (61,62).
At present, there is no solid evidence to consider these 
as risk medications in relation to ONJ, given that there 
are no data to demonstrate a statistically significant 
greater incidence than in other population groups. 
Furthermore, there is no objective risk estimation that 
could potentially be used, and there is little knowledge 
on the etiopathogenic mechanism that could cause this 
adverse effect. In any case, considering the possibility 
of new cases appearing in the future and of being able 
to more definitely establish this association, it would be 
advisable to treat these patients with prevention proto-
cols similar to the ones used for those taking antiresorp-
tives or antiangiogenics.
The mechanism by which these drugs could increase 
the risk of ONJ has not yet been established. In the 
case of the anti-TNFα, their use could produce the in-
hibition of the bone remodeling at the cost of an inhibi-
tion of RANKL, with apoptosis induced by activated 
monocytes, or they could facilitate bone colonization 
by certain micro-organisms as a result of local im-
munosuppression (58-60,63). Table 4 lists the biologic 
immunomodulators for which cases of ONJ have been 
described, their brand name and the names of biosimilar 
products currently on the market.
- Other Immunomodulators
Corticoids: The long-term use of corticoids by the sys-
temic route increases the risk of suffering osteonecrosis 
or avascular necrosis (AVN) (64,65). AVN involves the 
death of bone tissue and its marrow due to impairment 
of the blood supply to the bone tissue. Its most common 
sites are the femur, tibia, humerus, calcaneus, or scaph-
oid (64,65). At an oral level, corticoids do not appear to 
be capable of causing MRONJ by themselves, although 
patients concomitantly administered bisphosphonates 
or denosumab could have an increased risk of develop-
ing it (21,66,67).
Active ingredient Route ad-
min.




Bevacizumab IV Anti-VEGF Avastin® Mvasi®
Aflibercept IV Anti-VEGF Zaltrap®, Eylea®
Pazopanib PO Anti-VEGF Votrient®
Cabozantinib PO Anti-VEGF Carbometyx® Cometriq®
Sunitinib PO Anti-TKI Sutent® Sunitinib malate
Axitinib PO Anti-TKI Inlyta®
Dasatinib PO Anti-TKI Sprycell® Dasatinib
Imatinib PO Anti-TKI Glivec® Imatinib mesylate
Gleevec®
Erlotinib PO Anti-TKI Tarceva® Erlotinib hydrochloride
Sorafenib PO Anti-TKI Nexavar® Sorafenib
Table 3: Antiangiogenics cited in the text: brand names, action mechanism and route of administration.
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Methotrexate: Methotrexate (MTX) is one of the key 
drugs used in the treatment of rheumatoid arthritis 
(RA) and other autoimmune disorders and inflamma-
tory diseases (68).  Furthermore, it is a cytotoxic medi-
cation that is indicated in the treatment of a number of 
solid tumors and haematological malignancies (68,69). 
The association of MTX with ONJ has some contro-
versial aspects. Thus, in many cases described in the 
literature, in addition to MTX, patients had also been 
treated previously or concomitantly with bisphospho-
nates and/or corticoids (70). On the other hand, in some 
cases, the presence of necrotic bone could be secondary 
to a Methotrexate-related chronic lymphoproliferative 
disorder and it would therefore be arguable whether it 
should be considered as MRONJ, in the absence of a de-
tailed histopathological study of the lesion (71). Howev-
er, authors such as Henien et al. (72), have recently de-
scribed cases of MRONJ in patients treated for RA with 
low oral doses of MTX over long periods of time, in the 
absence of a lymphoproliferative disorder and with no 
administration of other antiresorptive or antiangiogenic 
medications. The exact etiopathogenic mechanism of 
its possible association with MRONJ is unknown, al-
though it appears to be primarily associated with its im-
munomodulating effects. MTX inhibits DNA synthesis, 
cell proliferation in the S phase cell cycle, it is cytotoxic 
in high doses while in low doses in inhibits T and B 
lymphocyte functions and proliferation, and inhibits the 
release of IL-1, TNFα and other cytokines (73,74). How-
ever, it could also be partly related to its great capacity 
to inhibit osteoblast proliferation (73,74).
mTOR inhibitors: Everolimus and Temsirolimus are 
inhibitors of mTOR (mammalian target of rapamycin) 
Active ingredient Route 
admin.




Infliximab IV Anti-TNFα Remicade® Flixabi®, Inflectra®, Remsima®, Renflexis®, 
Ixifi®, Zessly®
Adalimumab IV Anti-TNFα Humira® Amjevita®, Amgevita® Solymbic®, Imraldi®, 
Cyltezo®, Hulio®, Hefiya®, Halimatoz®, Hyri-
moz®, Trudexa®
Rituximab IV Anti-CD20 Mabthera® Truxima®, Rixathon®, Riximyo®,*Ritemvia®, 
Rituzena®,*Blitzima®, Rituxan®, Rituxan Hycela®






Methotrexate PO/IV Generic: Methotrexate
Imeth®, Metoject®, Nordimet®, 
Bertanel®, Glofer®, Quinux®
Methotrexate sodium
Folex ®, Abitrexate® , Mexate®, Otrexup Rasuvo®, 
Trexall®, Xatmep®
Temsirolimus IV Torisel®
Everolimus PO Certican®, Afinitor®, Votubia®
Table 4: Immunomodulators cited in the text: brand names and route of administration.
with antiangiogenic and immunosuppressive properties 
(75,76). They are primarily used to prevent transplant 
rejection and, at higher doses, they are used in the treat-
ment of advanced stages of breast and kidney cancer, 
some neuroendocrine tumors and some types of leuke-
mia (75,76). Most of the MRONJ related to Everolimus 
or Temsirolimus have been described in patients si-
multaneously receiving bisphosphonates (77,78), deno-
sumab (79) or other antiangiogenics (80,81). However, 
MRONJ cases have recently been described in patients 
solely treated with Everolimus (82). The MRONJ cas-
es described in the literature and associated with the 
mTOR inhibitors, do not appear to have different clini-
cal characteristics to those associated with other medi-
cations (77-82). Given the paucity of clinical cases de-
scribed up to now, it is not possible to estimate the level 
of risk for these medications in relation to MRONJ.
Table 4 also provides a summary of the brand names 
of the non-biologic immunomodulators associated with 
MRONJ.
- Other medications
Isolated cases of MRONJ have been described for other 
drugs, although it has not yet been possible to com-
pletely clarify the etiopathogenesis for this possible re-
lationship. These drugs include ipilimumab (Yervoy®), 
an anti-CTLA-4 monoclonal antibody indicated for the 
treatment of advanced melanoma (83) or azacitidine 
(Vidaza®), a chemotherapy drug used in the treatment 
of some types of myelodysplastic syndromes and leuke-
mia (84). At present, new investigations are required in 
order to ascertain whether these medications are related 
to a risk of MRONJ.
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Discussion
15 years after the first cases were reported relating to the 
development of ONJ with the use of bisphosphonates, 
there is still no effective treatment despite the differ-
ent therapeutic options available (1,21-24). Prevention 
is key to controlling this severe pathology, which can 
have an important effect on a patient’s quality of life 
(21-23). Its prevalence is extremely variable, depend-
ing on the drug, cause, duration and prescription dose, 
and the existence of other concomitant pathologies. The 
risk is low for those patients taking bisphosphonates 
or denosumab orally for osteoporosis and with no ad-
ministration of corticoids and not suffering from other 
pathologies (21-23). However, this risk increases con-
siderably from the fourth year of treatment onwards and 
is far higher in those patients receiving the intravenous 
administration of bisphosphonates. With regard to other 
medications, it is difficult to do a risk estimate due to 
the paucity of studies with a high level of evidence. 
Although MRONJ may develop spontaneously, more 
than 60%-70% of cases, primarily dependent on the 
type of medication, occur following a dental extraction, 
implant surgery or any other type of jaw surgery (21-
23). On occasions, even excessive pressure or a decu-
bitus ulcer caused by removable dentures may trigger 
one of these lesions (21-23). Therefore, in view of the 
foregoing, in order to prevent MRONJ, it is essential for 
all healthcare professionals to have a thorough knowl-
edge of the key clinicopathologic and etiopathogenic 
principles of this pathology. 
Reviewing the literature, it can be observed how new 
drugs have been progressively added over the last few 
years to the list of drugs related to MRONJ, with a vary-
ing level of evidence. The patent of some biologic medi-
cations related to MRONJ has recently expired and, fol-
lowing approval, its biosimilar products have started to 
be used, although obviously to a lesser extent than the 
original products. Biosimilar drugs are not exact copies 
of the original biologic medication. However, they are 
designed to have the same biologic effect and, therefore, 
their possible adverse effects could also be very simi-
lar. Moreover, looking at the clinical trial registers such 
as ClinicalTrials.gov or EU Clinical Trials Registers, 
many more biosimilar medications related to MRONJ 
are already close to being marketed.
In view of the serious public health problem caused by 
MRONJ, it appears to be extremely important to ensure 
that all healthcare professionals are fully up-to-date 
with the complete list of risk medications, prevention 
protocols and consent documents prepared by the dif-
ferent entities and organizations in this field. Unfortu-
nately, many of the documents available for consent, 
positioning and action protocols for this type of patient, 
are not up-to-date and do not include information on the 
drugs that have most recently come to be suspected of 
causing this side effect.
Conclusions
Not only bisphosphonates are capable of inducing ONJ. 
A growing list of medications probably have this same 
side effect, with a higher or lower risk.  Although a high 
level of evidence does not exist for these medications, 
it would be important, from a preventive point of view, 
to apply clinical protocols that are the same or similar 
to the ones used for patients administered bisphospho-
nates or denosumab. Over the next 2 to 3 years, it would 
be advisable to treat with particular care those patients 
under treatment with new biologic antiresorptives and 
anti-inflammatory drugs, and any other new antiangio-
genic or immunosuppressant.
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